The Global Health Body Issues Warning Over Acute Shortage of Obesity Injections

Fewer than 10% of patients eligible to benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it issues its initial guidance on the medications.

Given over a billion individuals worldwide now obese, it is urging more widespread and fairer access to these injectable treatments.

Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"The latest guidelines affirms that obesity is a lifelong illness that can be addressed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are major barriers to widespread access to the treatments that can help people shift substantial weight, explains the agency.

Skinny Jab Shortage

Even in the current most favorable case, the production of such drugs might only reach around 100 million people – under 10% of eligible patients, per the health organization.

The recommendation urges governments and firms to expand access, by measures including patent sharing.

A patent on a key compound – the primary component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.

How Obesity Jabs Operate

These medications mimick a natural hormone to slow digestion, suppress the appetite and increase feelings of fullness so people eat less.

Patients commonly see weight reduction in the initial weeks of commencing the regular doses.

Evidence indicates patients may put most of the weight back on after a year of discontinuing the treatment, as their usual food cravings resume.

To be carrying excess weight elevates your risk for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.

Excess weight impacts individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.